Workup for Progressive Thrombocytosis in an 83-Year-Old
In an 83-year-old with platelets rising from 574 to 704 over 3 months, you must first distinguish primary from secondary thrombocytosis through repeat CBC with differential, peripheral blood smear, inflammatory markers (CRP), and iron studies with ferritin—then proceed to JAK2 mutation testing if no secondary cause is identified 1.
Initial Laboratory Assessment
Start with these specific tests to differentiate primary versus secondary causes:
- Repeat CBC with differential and peripheral blood smear to confirm persistent thrombocytosis and evaluate for myeloproliferative features 1
- CRP and ESR to assess for inflammation/infection
- Iron studies with ferritin to exclude iron deficiency (a common secondary cause)
- Review for secondary causes: tissue damage, infection, malignancy, chronic inflammation 2
The distinction matters critically because primary thrombocytosis carries significantly higher risk of arterial and venous thromboembolism, while secondary thrombocytosis only increases venous thrombosis risk when other risk factors are present 2.
Key Discriminating Features
Laboratory parameters that favor primary over secondary thrombocytosis 2:
- Higher absolute platelet counts
- Elevated leukocyte count
- Elevated hematocrit
- Elevated LDH and serum potassium
- Lower ESR and fibrinogen (compared to secondary causes)
If No Secondary Cause Identified
Proceed with molecular testing in this sequence 1:
- JAK2 V617F mutation (first-line)
- If JAK2 negative: CALR and MPL mutations
- Bone marrow biopsy to confirm essential thrombocythemia
This patient's age (83 years) and rising platelet trend over 3 months makes essential thrombocythemia a serious consideration, as primary thrombocytosis occurs in 12-14% of all thrombocytosis cases 2, 3.
Risk Stratification Context
At 83 years old, this patient automatically falls into high-risk category for essential thrombocythemia based on age >60 years alone 4. The NCCN guidelines emphasize that advanced age (>60 years) is one of the two most consistent risk factors for thrombosis 4.
Clinical Red Flags to Assess
Specifically evaluate for symptoms suggesting primary myeloproliferative neoplasm:
- Microvascular symptoms: headaches, paresthesias, erythromelalgia, chest pain
- Splenomegaly (symptomatic or progressive)
- Constitutional symptoms: pruritus, night sweats, fatigue
- Prior thrombotic events (arterial or venous)
- Bleeding manifestations or acquired von Willebrand disease
Primary thrombocytosis patients experience bleeding/vaso-occlusive symptoms in 56% of cases, versus only 4% in secondary thrombocytosis 3.
Important Caveats
- Extreme thrombocytosis (>1000 × 10⁹/L) is actually more commonly reactive (82%) than primary (14%) 3, but this patient's moderate elevation with upward trend requires full evaluation
- Even at platelet counts >1000, mortality from thrombotic/bleeding events during the thrombocytotic period is rare in both primary and secondary causes 3
- However, untreated primary thrombocytosis carries ongoing thrombotic risk that persists beyond the acute period
The workup should proceed urgently given the patient's age-related high-risk status and the progressive nature of the thrombocytosis.